vs
Side-by-side financial comparison of Hologic (HOLX) and LOGITECH INTERNATIONAL S.A. (LOGI). Click either name above to swap in a different company.
LOGITECH INTERNATIONAL S.A. is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.4× Hologic). LOGITECH INTERNATIONAL S.A. runs the higher net margin — 17.7% vs 17.1%, a 0.6% gap on every dollar of revenue. On growth, LOGITECH INTERNATIONAL S.A. posted the faster year-over-year revenue change (6.1% vs 2.5%). LOGITECH INTERNATIONAL S.A. produced more free cash flow last quarter ($465.6M vs $215.2M). Over the past eight quarters, LOGITECH INTERNATIONAL S.A.'s revenue compounded faster (18.5% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Logitech International S.A. is a Swiss multinational manufacturer of computer peripherals and software. Headquartered in Lausanne, Switzerland, the company has offices throughout Europe, Asia, Oceania, and the Americas. It is a component of the Swiss Market Index, and is listed on the Nasdaq.
HOLX vs LOGI — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.4B |
| Net Profit | $179.1M | $251.0M |
| Gross Margin | 56.0% | 43.2% |
| Operating Margin | 22.6% | 20.1% |
| Net Margin | 17.1% | 17.7% |
| Revenue YoY | 2.5% | 6.1% |
| Net Profit YoY | -10.9% | 25.4% |
| EPS (diluted) | $0.79 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $988.0M | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $1.0B | $1.0B |
| Q4 25 | $179.1M | $251.0M | ||
| Q3 25 | $187.2M | $170.7M | ||
| Q2 25 | $194.9M | $146.0M | ||
| Q1 25 | $-17.4M | $144.1M | ||
| Q4 24 | $201.0M | $200.1M | ||
| Q3 24 | $178.6M | $145.5M | ||
| Q2 24 | $194.5M | $141.8M | ||
| Q1 24 | $169.9M | $167.6M |
| Q4 25 | 56.0% | 43.2% | ||
| Q3 25 | 55.6% | 43.4% | ||
| Q2 25 | 56.3% | 41.7% | ||
| Q1 25 | 37.5% | 43.1% | ||
| Q4 24 | 56.8% | 42.9% | ||
| Q3 24 | 56.4% | 43.6% | ||
| Q2 24 | 55.4% | 42.8% | ||
| Q1 24 | 53.3% | 43.2% |
| Q4 25 | 22.6% | 20.1% | ||
| Q3 25 | 22.6% | 16.1% | ||
| Q2 25 | 24.9% | 14.1% | ||
| Q1 25 | -0.7% | 10.5% | ||
| Q4 24 | 22.5% | 17.5% | ||
| Q3 24 | 23.3% | 14.4% | ||
| Q2 24 | 24.1% | 14.1% | ||
| Q1 24 | 20.7% | 12.9% |
| Q4 25 | 17.1% | 17.7% | ||
| Q3 25 | 17.8% | 14.4% | ||
| Q2 25 | 19.0% | 12.7% | ||
| Q1 25 | -1.7% | 14.3% | ||
| Q4 24 | 19.7% | 14.9% | ||
| Q3 24 | 18.1% | 13.0% | ||
| Q2 24 | 19.2% | 13.0% | ||
| Q1 24 | 16.7% | 16.6% |
| Q4 25 | $0.79 | $1.69 | ||
| Q3 25 | $0.84 | $1.15 | ||
| Q2 25 | $0.86 | $0.98 | ||
| Q1 25 | $-0.08 | $0.94 | ||
| Q4 24 | $0.87 | $1.32 | ||
| Q3 24 | $0.75 | $0.95 | ||
| Q2 24 | $0.82 | $0.92 | ||
| Q1 24 | $0.72 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $1.8B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.3B |
| Total Assets | $9.2B | $4.1B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $1.8B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.3B | $1.4B | ||
| Q2 24 | $2.4B | $1.5B | ||
| Q1 24 | $2.2B | $1.5B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $2.3B | ||
| Q3 25 | $5.0B | $2.1B | ||
| Q2 25 | $4.8B | $2.2B | ||
| Q1 25 | $4.6B | $2.1B | ||
| Q4 24 | $4.8B | $2.1B | ||
| Q3 24 | $5.1B | $2.1B | ||
| Q2 24 | $5.0B | $2.2B | ||
| Q1 24 | $4.8B | $2.2B |
| Q4 25 | $9.2B | $4.1B | ||
| Q3 25 | $9.0B | $3.7B | ||
| Q2 25 | $8.8B | $3.7B | ||
| Q1 25 | $8.5B | $3.5B | ||
| Q4 24 | $8.7B | $3.7B | ||
| Q3 24 | $9.2B | $3.6B | ||
| Q2 24 | $8.9B | $3.7B | ||
| Q1 24 | $8.7B | $3.6B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $480.5M |
| Free Cash FlowOCF − Capex | $215.2M | $465.6M |
| FCF MarginFCF / Revenue | 20.5% | 32.8% |
| Capex IntensityCapex / Revenue | 1.4% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.91× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $903.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $480.5M | ||
| Q3 25 | $355.1M | $228.8M | ||
| Q2 25 | $343.3M | $125.0M | ||
| Q1 25 | $169.4M | $129.7M | ||
| Q4 24 | $189.3M | $370.9M | ||
| Q3 24 | $367.0M | $166.0M | ||
| Q2 24 | $405.8M | $176.0M | ||
| Q1 24 | $292.4M | $239.1M |
| Q4 25 | $215.2M | $465.6M | ||
| Q3 25 | $341.4M | $212.3M | ||
| Q2 25 | $330.5M | $108.8M | ||
| Q1 25 | $153.9M | $116.9M | ||
| Q4 24 | $172.5M | $356.6M | ||
| Q3 24 | $350.6M | $151.5M | ||
| Q2 24 | $385.3M | $161.4M | ||
| Q1 24 | $279.6M | $228.8M |
| Q4 25 | 20.5% | 32.8% | ||
| Q3 25 | 32.5% | 17.9% | ||
| Q2 25 | 32.3% | 9.5% | ||
| Q1 25 | 15.3% | 11.6% | ||
| Q4 24 | 16.9% | 26.6% | ||
| Q3 24 | 35.5% | 13.6% | ||
| Q2 24 | 38.1% | 14.8% | ||
| Q1 24 | 27.5% | 22.6% |
| Q4 25 | 1.4% | 1.0% | ||
| Q3 25 | 1.3% | 1.4% | ||
| Q2 25 | 1.3% | 1.4% | ||
| Q1 25 | 1.5% | 1.3% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 2.0% | 1.3% | ||
| Q1 24 | 1.3% | 1.0% |
| Q4 25 | 1.28× | 1.91× | ||
| Q3 25 | 1.90× | 1.34× | ||
| Q2 25 | 1.76× | 0.86× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | 0.94× | 1.85× | ||
| Q3 24 | 2.05× | 1.14× | ||
| Q2 24 | 2.09× | 1.24× | ||
| Q1 24 | 1.72× | 1.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LOGI
| Retail Gaming | $482.7M | 34% |
| Retail Keyboards Desktops | $254.6M | 18% |
| Retail Pointing Devices | $241.2M | 17% |
| Retail Video Collaboration | $193.3M | 14% |
| Retail Tablet And Other Accessories | $93.6M | 7% |
| Retail Webcams | $82.3M | 6% |
| Retail Headsets | $45.9M | 3% |
| Other Retail Products | $28.0M | 2% |
